Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00722098 · ClinicalTrials.gov registry record · Phase 2
Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients
A Phase 2 study, sponsored by Baylor Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00722098 is a Phase 2 study that was terminated before completion, run by Baylor Research Institute. The registered enrollment target is 9 participants.
The verdict
NCT00722098, a Phase 2 study, was terminated before completion, sponsored by Baylor Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.
Interventions
- BIOLOGICAL DC Vaccine & Cyclophosphamide
- BIOLOGICAL DC Vaccine & Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00722098
The ClinicalTrials.gov registry entry for NCT00722098 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DC Vaccine & Cyclophosphamide is the first listed.
NCT00722098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00722098 about?
NCT00722098 is a clinical study titled "Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients". The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.
What is the current status of trial NCT00722098?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2008-06. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00722098?
The interventions under investigation include: DC Vaccine & Cyclophosphamide (BIOLOGICAL), DC Vaccine & Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00722098?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.